Limits...
Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.

Kishimoto M, Noda M - Clin Drug Investig (2015)

Bottom Line: On days 1, 3, and 5, blood was drawn for plasma glucose, serum C-peptide, plasma glucagon, total and active glucagon-like peptide-1 (GLP-1), and total and active glucose-dependent insulinotropic peptide (GIP) measurements.Coadministration of anagliptin with miglitol resulted in additional improvements in glycemic control over the entire day in three of the four patients.The C-peptide, glucagon, and total and active GLP-1 and GIP responded differently to the medications for each patient, suggesting interindividual differences in hormonal responses, which may be complicated by multifactorial effects.

View Article: PubMed Central - PubMed

Affiliation: Department of Diabetes, Endocrinology, and Metabolism, Center Hospital, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan, miyakok@fides.dti.ne.jp.

ABSTRACT
The aim of this case study was to examine the efficacy of a dipeptidyl peptidase-4 inhibitor (anagliptin) and an α-glucosidase inhibitor (miglitol) when added to ongoing insulin treatment in patients with type 2 diabetes mellitus. Continuous glucose monitoring was performed in four Japanese insulin-treated inpatients with type 2 diabetes. Baseline data were collected on day 1. Miglitol was administered on days 2 and 3. On day 4, miglitol and anagliptin were coadministered before breakfast. On days 1, 3, and 5, blood was drawn for plasma glucose, serum C-peptide, plasma glucagon, total and active glucagon-like peptide-1 (GLP-1), and total and active glucose-dependent insulinotropic peptide (GIP) measurements. Coadministration of anagliptin with miglitol resulted in additional improvements in glycemic control over the entire day in three of the four patients. The C-peptide, glucagon, and total and active GLP-1 and GIP responded differently to the medications for each patient, suggesting interindividual differences in hormonal responses, which may be complicated by multifactorial effects.

Show MeSH

Related in: MedlinePlus

Continuous glucose monitoring (CGM) results for cases 1–4 under the conditions of insulin administration, coadministration of insulin and miglitol, and coadministration of insulin, miglitol, and anagliptin
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4300407&req=5

Fig1: Continuous glucose monitoring (CGM) results for cases 1–4 under the conditions of insulin administration, coadministration of insulin and miglitol, and coadministration of insulin, miglitol, and anagliptin

Mentions: Figure 1 shows the representative CGM results of each patient. In case 1, the glucose levels and fluctuations after miglitol administration were not remarkably attenuated but were attenuated when miglitol and anagliptin were coadministered. In case 2, the glucose levels and fluctuations were not remarkably attenuated even after the administration of miglitol alone or coadministration of miglitol and anagliptin. In cases 3 and 4, the glucose levels and fluctuations after miglitol administration were attenuated, and this attenuation was even more pronounced with the combination of miglitol and anagliptin. The accuracy of these measurements was reflected in the mean and standard deviation (SD) values of the CGM measurements (Table 2).Fig. 1


Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.

Kishimoto M, Noda M - Clin Drug Investig (2015)

Continuous glucose monitoring (CGM) results for cases 1–4 under the conditions of insulin administration, coadministration of insulin and miglitol, and coadministration of insulin, miglitol, and anagliptin
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4300407&req=5

Fig1: Continuous glucose monitoring (CGM) results for cases 1–4 under the conditions of insulin administration, coadministration of insulin and miglitol, and coadministration of insulin, miglitol, and anagliptin
Mentions: Figure 1 shows the representative CGM results of each patient. In case 1, the glucose levels and fluctuations after miglitol administration were not remarkably attenuated but were attenuated when miglitol and anagliptin were coadministered. In case 2, the glucose levels and fluctuations were not remarkably attenuated even after the administration of miglitol alone or coadministration of miglitol and anagliptin. In cases 3 and 4, the glucose levels and fluctuations after miglitol administration were attenuated, and this attenuation was even more pronounced with the combination of miglitol and anagliptin. The accuracy of these measurements was reflected in the mean and standard deviation (SD) values of the CGM measurements (Table 2).Fig. 1

Bottom Line: On days 1, 3, and 5, blood was drawn for plasma glucose, serum C-peptide, plasma glucagon, total and active glucagon-like peptide-1 (GLP-1), and total and active glucose-dependent insulinotropic peptide (GIP) measurements.Coadministration of anagliptin with miglitol resulted in additional improvements in glycemic control over the entire day in three of the four patients.The C-peptide, glucagon, and total and active GLP-1 and GIP responded differently to the medications for each patient, suggesting interindividual differences in hormonal responses, which may be complicated by multifactorial effects.

View Article: PubMed Central - PubMed

Affiliation: Department of Diabetes, Endocrinology, and Metabolism, Center Hospital, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan, miyakok@fides.dti.ne.jp.

ABSTRACT
The aim of this case study was to examine the efficacy of a dipeptidyl peptidase-4 inhibitor (anagliptin) and an α-glucosidase inhibitor (miglitol) when added to ongoing insulin treatment in patients with type 2 diabetes mellitus. Continuous glucose monitoring was performed in four Japanese insulin-treated inpatients with type 2 diabetes. Baseline data were collected on day 1. Miglitol was administered on days 2 and 3. On day 4, miglitol and anagliptin were coadministered before breakfast. On days 1, 3, and 5, blood was drawn for plasma glucose, serum C-peptide, plasma glucagon, total and active glucagon-like peptide-1 (GLP-1), and total and active glucose-dependent insulinotropic peptide (GIP) measurements. Coadministration of anagliptin with miglitol resulted in additional improvements in glycemic control over the entire day in three of the four patients. The C-peptide, glucagon, and total and active GLP-1 and GIP responded differently to the medications for each patient, suggesting interindividual differences in hormonal responses, which may be complicated by multifactorial effects.

Show MeSH
Related in: MedlinePlus